A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Solid Tumors Clinical Trial

Official title:

An Open-label, Phase I Dose Escalation Followed by Dose Expansion Trial in Patients With Advanced Solid Tumours to Investigate Safety, Pharmacokinetics, and Efficacy and to Select the Dose for Further Development of BI 770371 in Combination With Ezabenlimab

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05327946
• Other study ID #: 1501-0001
• Status: Recruiting
• Phase: Phase 1
• Start date: May 9, 2022
• Est. completion date: January 24, 2025

Study information

• Verified date: April 2024
• Source: Boehringer Ingelheim
• Contact: Boehringer Ingelheim
• Phone: 1-800-243-0127
• Email: clintriage.rdg[@]boehringer-ingelheim.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful and for whom no other treatment options exist can join the study.

The purpose of this study is to find the highest dose of BI 770371 that people with advanced cancer can tolerate when taken alone or together with a medicine called ezabenlimab.

BI 770371 and ezabenlimab are antibodies that may help the immune system fight cancer (checkpoint inhibitors). In this study, BI 770371 is given to people for the first time.

Participants get BI 770371 alone or together with ezabenlimab as an infusion every 3 weeks.

It is planned that participants can stay in the study for up to 2 years, if they benefit from treatment and can tolerate it. During this time, they visit the study site regularly.

The doctors collect information on any health problems of the participants. The doctors also regularly monitor the size of the tumour.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 42
• Est. completion date: January 24, 2025
• Est. primary completion date: July 19, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

• Patients =18 years of age and over the legal age of consent as required by local legislation at the time of signature of the ICF

• Presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) v1.1

• Eastern Cooperative Oncology Group (ECOG) Score: 0 to 1

• Life expectancy =3 months at the start of treatment in the opinion of the Investigator.

• Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type)

• Patients who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not eligible for established treatment options (including anti-Programmed Cell Death 1 (PD-1) or anti-Programmed Death-Ligand 1 (PD-L1) therapies, if relevant). Patients must have exhausted available treatment options known to prolong survival for their disease

• All toxicities related to previous anti-cancer therapies have resolved = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia, peripheral neuropathy and endocrinopathies considered irreversible [like hypothyroidism], and amenorrhea/menstrual disorders which can be any grade) Further inclusion criteria apply

Exclusion Criteria:

• Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to randomisation or planned within 12 months after screening, e.g. hip replacement

• Presence of active invasive cancers other than the one treated in this trial within 5 years prior to screening, with the exception of appropriately treated basal-cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or other local tumours considered cured by local treatment

• Untreated brain metastasis(es) that may be considered active. Patients with previously treated brain metastases may participate provided they are stable (i.e., without evidence of Progressive Disease (PD) by imaging for at least 4 weeks prior to the first dose of trial treatment, and any neurologic symptoms have returned to baseline), and there is no evidence of new or enlarging brain metastases

• Radiotherapy within 4 weeks prior to randomisation except as follows:

• Palliative radiotherapy to regions other than the chest is allowed if completed at least 2 weeks prior to randomisation

• Single dose palliative radiotherapy for symptomatic metastasis within 2 weeks prior to randomisation may be allowed but must be discussed with the Sponsor

• Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial

• History of pneumonitis within the last 5 years or Interstitial lung disease

• Known history of allergy to any trial drug, or any excipients of the trial drug(s)

• History of severe hypersensitivity reactions and/or severe infusion related reactions (Grade = 3 National Cancer Institute (NCI) CTCAE v5.0) to other Monoclonal Antibodies (mAbs) Further exclusion criteria apply

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• BI 770371
BI 770371
• ezabenlimab
ezabenlimab

Locations

Country	Name	City	State
Canada	Centre Hospitalier de l'Universite de Montreal (CHUM)	Montreal	Quebec
Japan	National Cancer Center Hospital East	Chiba, Kashiwa
Japan	National Cancer Center Hospital	Tokyo, Chuo-ku
United States	John Theurer Cancer Center	Hackensack	New Jersey
United States	Florida Cancer Specialists	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Canada,  Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period in monotherapy		21 days
Primary	Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period in combination therapy		21 days
Secondary	Occurrence of Adverse Events (AEs) during the on-treatment period in monotherapy		up to 2 years
Secondary	Occurrence of Adverse Events (AEs) during the on-treatment period in combination therapy		up to 2 years
Secondary	Occurrence of Dose Limiting Toxicities (DLTs) during the on-treatment period in monotherapy		up to 2 years
Secondary	Occurrence of Dose Limiting Toxicities (DLTs) during the on-treatment period in combination therapy		up to 2 years

External Links

•   Related Info